J&J beats earnings estimates; Middle East conflict weighs on medical device sales
- J&J beats Q3 estimates with $25.4 billion in revenue, but Wall Street dumps the stock anyway.
- Tremfya sales surge 68% as the pharma giant tries to outrun the Stelara patent cliff.
- Middle East conflict hits bottom line; foreign governments trading heart pumps for defense budgets.
- Abiomed heart pump business continues to flatline following damaging UK study.
- Hips and knees division on the chopping block as spin-off plans accelerate.
Brief Summary
Johnson & Johnson managed to squeeze out a quarterly earnings beat, but the market wasn't buying it. While their pharmaceutical arm—specifically the blockbuster drug Tremfya—is firing on all cylinders, the medical technology division is running into a geopolitical buzzsaw. Foreign markets are tightening their belts, prioritizing defense spending over premium medical devices as global instability takes a bite out of international revenue.
Why This Matters
When a healthcare titan like J&J struggles to move medical devices abroad, it highlights just how fragile the global supply chain and healthcare economies have become. If international demand keeps shifting away from elective procedures and high-end medical tech toward military spending, you could see a ripple effect in the availability and cost of specialized medical equipment. Furthermore, as J&J shifts its focus toward spinning off its orthopedics unit, expect more consolidation and corporate maneuvering that will eventually dictate the costs and options available to you the next time you step into a hospital or surgical center.